JP2014519809A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014519809A5 JP2014519809A5 JP2014508143A JP2014508143A JP2014519809A5 JP 2014519809 A5 JP2014519809 A5 JP 2014519809A5 JP 2014508143 A JP2014508143 A JP 2014508143A JP 2014508143 A JP2014508143 A JP 2014508143A JP 2014519809 A5 JP2014519809 A5 JP 2014519809A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- domain
- amino acid
- acid sequence
- rnase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710163270 Nuclease Proteins 0.000 claims description 59
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 229920001184 polypeptide Polymers 0.000 claims description 44
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 44
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 16
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 16
- 102000006382 Ribonucleases Human genes 0.000 claims description 16
- 108010083644 Ribonucleases Proteins 0.000 claims description 16
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 238000003259 recombinant expression Methods 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 231100000433 cytotoxic Toxicity 0.000 claims description 3
- 230000001472 cytotoxic effect Effects 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 208000004300 Atrophic Gastritis Diseases 0.000 claims description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims description 2
- 206010071155 Autoimmune arthritis Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 102000000989 Complement System Proteins Human genes 0.000 claims description 2
- 108010069112 Complement System Proteins Proteins 0.000 claims description 2
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 208000036495 Gastritis atrophic Diseases 0.000 claims description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 101000845618 Homo sapiens Deoxyribonuclease gamma Proteins 0.000 claims description 2
- 102000009490 IgG Receptors Human genes 0.000 claims description 2
- 108010073807 IgG Receptors Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 208000007466 Male Infertility Diseases 0.000 claims description 2
- 206010028665 Myxoedema Diseases 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 claims description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 claims description 2
- 206010034277 Pemphigoid Diseases 0.000 claims description 2
- 201000011152 Pemphigus Diseases 0.000 claims description 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 2
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000018631 connective tissue disease Diseases 0.000 claims description 2
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 102000054371 human DNASE1L3 Human genes 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 230000011488 interferon-alpha production Effects 0.000 claims description 2
- 201000002364 leukopenia Diseases 0.000 claims description 2
- 231100001022 leukopenia Toxicity 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 208000003786 myxedema Diseases 0.000 claims description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 2
- 208000015385 phacoanaphylactic uveitis Diseases 0.000 claims description 2
- 231100000572 poisoning Toxicity 0.000 claims description 2
- 230000000607 poisoning effect Effects 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 206010036601 premature menopause Diseases 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 108010036169 three prime repair exonuclease 1 Proteins 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000000539 dimer Substances 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 238000000034 method Methods 0.000 description 6
- 230000000593 degrading effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161480961P | 2011-04-29 | 2011-04-29 | |
| US61/480,961 | 2011-04-29 | ||
| US201261617241P | 2012-03-29 | 2012-03-29 | |
| US61/617,241 | 2012-03-29 | ||
| PCT/US2012/035614 WO2012149440A2 (en) | 2011-04-29 | 2012-04-27 | Therapeutic nuclease compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016243950A Division JP2017114854A (ja) | 2011-04-29 | 2016-12-16 | 治療用ヌクレアーゼ組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014519809A JP2014519809A (ja) | 2014-08-21 |
| JP2014519809A5 true JP2014519809A5 (https=) | 2015-06-18 |
| JP6063450B2 JP6063450B2 (ja) | 2017-01-18 |
Family
ID=47073103
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508143A Active JP6063450B2 (ja) | 2011-04-29 | 2012-04-27 | 治療用ヌクレアーゼ組成物および方法 |
| JP2016243950A Pending JP2017114854A (ja) | 2011-04-29 | 2016-12-16 | 治療用ヌクレアーゼ組成物および方法 |
| JP2018177009A Active JP6762345B2 (ja) | 2011-04-29 | 2018-09-21 | 治療用ヌクレアーゼ組成物および方法 |
| JP2020150220A Active JP7212016B2 (ja) | 2011-04-29 | 2020-09-08 | 治療用ヌクレアーゼ組成物および方法 |
| JP2023003096A Active JP7551794B2 (ja) | 2011-04-29 | 2023-01-12 | 治療用ヌクレアーゼ組成物および方法 |
| JP2024077060A Pending JP2024099851A (ja) | 2011-04-29 | 2024-05-10 | 治療用ヌクレアーゼ組成物および方法 |
| JP2024151150A Pending JP2024167368A (ja) | 2011-04-29 | 2024-09-03 | 治療用ヌクレアーゼ組成物および方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016243950A Pending JP2017114854A (ja) | 2011-04-29 | 2016-12-16 | 治療用ヌクレアーゼ組成物および方法 |
| JP2018177009A Active JP6762345B2 (ja) | 2011-04-29 | 2018-09-21 | 治療用ヌクレアーゼ組成物および方法 |
| JP2020150220A Active JP7212016B2 (ja) | 2011-04-29 | 2020-09-08 | 治療用ヌクレアーゼ組成物および方法 |
| JP2023003096A Active JP7551794B2 (ja) | 2011-04-29 | 2023-01-12 | 治療用ヌクレアーゼ組成物および方法 |
| JP2024077060A Pending JP2024099851A (ja) | 2011-04-29 | 2024-05-10 | 治療用ヌクレアーゼ組成物および方法 |
| JP2024151150A Pending JP2024167368A (ja) | 2011-04-29 | 2024-09-03 | 治療用ヌクレアーゼ組成物および方法 |
Country Status (28)
| Country | Link |
|---|---|
| US (6) | US10202588B2 (https=) |
| EP (2) | EP3449933A1 (https=) |
| JP (7) | JP6063450B2 (https=) |
| KR (6) | KR20250037576A (https=) |
| CN (2) | CN107964539B (https=) |
| AU (5) | AU2012249360B2 (https=) |
| BR (1) | BR112013027547B1 (https=) |
| CA (1) | CA2834626A1 (https=) |
| CL (1) | CL2013003123A1 (https=) |
| CO (1) | CO6811815A2 (https=) |
| CR (1) | CR20130598A (https=) |
| DK (1) | DK2704737T3 (https=) |
| DO (1) | DOP2013000250A (https=) |
| EA (1) | EA201391585A1 (https=) |
| EC (1) | ECSP13013060A (https=) |
| ES (1) | ES2666303T3 (https=) |
| HR (1) | HRP20180564T1 (https=) |
| HU (1) | HUE038759T2 (https=) |
| IL (5) | IL300276B2 (https=) |
| LT (1) | LT2704737T (https=) |
| MX (3) | MX351953B (https=) |
| NZ (1) | NZ616989A (https=) |
| PE (1) | PE20141172A1 (https=) |
| PH (1) | PH12013502441B1 (https=) |
| PL (1) | PL2704737T3 (https=) |
| SG (2) | SG10201913930UA (https=) |
| SI (1) | SI2704737T1 (https=) |
| WO (1) | WO2012149440A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX341084B (es) | 2009-11-02 | 2016-08-05 | Univ Washington | Composiciones de nucleasas terapéuticas y métodos. |
| ES2666303T3 (es) | 2011-04-29 | 2018-05-03 | University Of Washington | Composiciones terapéuticas de nucleasa y métodos |
| US9603907B2 (en) | 2012-02-01 | 2017-03-28 | Protalix Ltd. | Dry powder formulations of dNase I |
| CA2898184A1 (en) | 2013-01-16 | 2014-07-24 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
| HRP20192080T1 (hr) | 2013-10-31 | 2020-02-07 | Resolve Therapeutics, Llc | Terapeutske fuzije nukleaza-albumine i postupci |
| PL3110434T3 (pl) * | 2014-02-24 | 2019-01-31 | Takeda Gmbh | Białka fuzyjne uti |
| WO2015191546A2 (en) * | 2014-06-10 | 2015-12-17 | The Board Of Regents Of The University Of Texas System | Adp-ribose detection reagents |
| WO2016069889A1 (en) * | 2014-10-31 | 2016-05-06 | Resolve Therapeutics, Llc | Therapeutic nuclease-transferrin fusions and methods |
| US10117911B2 (en) | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
| KR102440820B1 (ko) | 2015-09-08 | 2022-09-05 | 테리피온, 인크. | ApoA-1 융합 폴리펩티드 및 관련 조성물 및 방법 |
| BR112018074453A2 (pt) | 2016-05-27 | 2019-03-19 | Abbvie Biotherapeutics Inc. | proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral |
| CA3029627A1 (en) * | 2016-07-01 | 2018-01-04 | Resolve Therapeutics, Llc | Optimized binuclease fusions and methods |
| WO2018136163A2 (en) | 2016-12-09 | 2018-07-26 | Theripion, Inc. | Tandem apoa-1 fusion polypeptides |
| CA3073537A1 (en) | 2017-08-22 | 2019-02-28 | Sanabio, Llc | Soluble interferon receptors and uses thereof |
| IL325846A (en) * | 2018-10-08 | 2026-03-01 | Neutrolis Inc | Engineering deoxyribonuclease enzymes for manufacturing and medicine |
| US10988746B2 (en) * | 2018-10-08 | 2021-04-27 | Neutrolis, Inc. | Manufacturing and engineering of DNASE enzymes for therapy |
| WO2020142740A1 (en) * | 2019-01-04 | 2020-07-09 | Resolve Therapeutics, Llc | Treatment of sjogren's disease with nuclease fusion proteins |
| JP2020136505A (ja) | 2019-02-20 | 2020-08-31 | 株式会社Ｊｏｌｅｄ | 半導体装置および表示装置 |
| IL294114A (en) * | 2020-01-11 | 2022-08-01 | Univ Yale | Preparations and methods for the treatment, improvement and/or prevention of diseases or disorders caused by or related to dnase1 and/or dnase1l3 |
| EP4161645A4 (en) * | 2020-06-08 | 2023-11-01 | Yale University | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING COAGULOPATHY AND/OR SEPSIS IN PATIENTS WITH BACTERIAL AND/OR VIRAL INFECTIONS |
| CN112088903A (zh) * | 2020-09-28 | 2020-12-18 | 武汉愔紫生物科技有限公司 | 一种大分子蛋白在抗菌抗病毒消毒剂中的应用 |
| JP2024507220A (ja) * | 2021-02-19 | 2024-02-16 | セリピオン， インコーポレイテッド | パラオキソナーゼ融合ポリペプチドならびに関連する組成物および方法 |
| CN115595315B (zh) * | 2021-06-28 | 2024-08-16 | 四川大学华西医院 | 核糖核酸酶i在抑制疼痛的药物中的新用途 |
| WO2026037276A1 (zh) * | 2024-08-12 | 2026-02-19 | 上海交通大学医学院 | 一种减少线粒体dna泄露的方法 |
Family Cites Families (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US5453269A (en) | 1986-04-14 | 1995-09-26 | The General Hospital Corporation | Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5559212A (en) | 1988-04-06 | 1996-09-24 | Alfacell Corporation | Frog embryo and egg-derived tumor cell anti-proliferation protein |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5840840A (en) | 1990-04-17 | 1998-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Selective RNase cytotoxic reagents |
| ES2133285T3 (es) | 1991-04-17 | 1999-09-16 | Medisup Int Nv | Polipeptidos hidrosolubles que tienen una alta afinidad para los interferones alfa y beta. |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| GB9300686D0 (en) | 1993-01-15 | 1993-03-03 | Imp Cancer Res Tech | Compounds for targeting |
| US20030108548A1 (en) | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
| US6348343B2 (en) | 1995-02-24 | 2002-02-19 | Genentech, Inc. | Human DNase I variants |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
| BR9606706A (pt) | 1995-10-16 | 1999-04-06 | Unilever Nv | Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo |
| US6482626B2 (en) | 1996-02-05 | 2002-11-19 | Genentech, Inc. | Human DNase |
| US6716974B1 (en) | 1996-05-31 | 2004-04-06 | Maine Medical Center Research Institute | Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids |
| US6391607B1 (en) | 1996-06-14 | 2002-05-21 | Genentech, Inc. | Human DNase I hyperactive variants |
| US7247302B1 (en) | 1996-08-02 | 2007-07-24 | Bristol-Myers Squibb Company | Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| DE69738522T2 (de) | 1996-08-02 | 2009-04-02 | Bristol-Myers Squibb Co. | Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| DK0932417T3 (da) | 1996-10-17 | 2003-04-14 | Immunomedics Inc | Non-antigent toxinkonjugat og fusionsprotein af internaliserende receptorsystem |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US20030068623A1 (en) | 1997-06-16 | 2003-04-10 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20020192659A1 (en) | 1997-09-17 | 2002-12-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6280991B1 (en) | 1997-10-15 | 2001-08-28 | Wisconsin Alumni Research Foundation | Engineered cytotoxic ribonclease |
| US5840296A (en) | 1997-10-15 | 1998-11-24 | Raines; Ronald T. | Engineered cytotoxic ribonuclease A |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| US6239257B1 (en) | 1998-12-30 | 2001-05-29 | Alfacell Corporation | Family of proteins belonging to the pancreatic ribonuclease a superfamily |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| IL147270A0 (en) | 1999-07-02 | 2002-08-14 | Genentech Inc | Fusion peptides comprising a peptide ligand domain and a multimerization domain |
| US6175003B1 (en) | 1999-09-10 | 2001-01-16 | Alfacell Corporation | Nucleic acids encoding ribonucleases and methods of making them |
| WO2001026608A2 (en) | 1999-10-14 | 2001-04-19 | Ledbetter Jeffrey A | Dna vaccines encoding antigen linked to a domain that binds cd40 |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| NZ527283A (en) | 2001-01-29 | 2006-03-31 | Biogen Idec Inc | Modified antibodies and methods of use |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| RU2003129528A (ru) | 2001-03-07 | 2005-04-10 | Мерк Патент ГмбХ (DE) | Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела |
| JP4586310B2 (ja) | 2001-07-04 | 2010-11-24 | 株式会社Ihi | セラミックス複合部材の製造方法 |
| US20060040262A1 (en) * | 2002-12-27 | 2006-02-23 | Morris David W | Novel compositions and methods in cancer |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| JP2006502091A (ja) | 2002-03-01 | 2006-01-19 | イミューノメディクス、インコーポレイテッド | クリアランス速度を高めるための二重特異性抗体点変異 |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| CA2489446A1 (en) | 2002-06-14 | 2003-12-24 | Wisconsin Alumni Research Foundation | Ribonuclease zymogen design |
| DK1534335T4 (en) | 2002-08-14 | 2015-10-05 | Macrogenics Inc | FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF |
| EP1553975B8 (en) | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| DK1562972T3 (da) | 2002-10-15 | 2010-12-06 | Facet Biotech Corp | Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese |
| EP1578367A4 (en) | 2002-11-01 | 2012-05-02 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES |
| GB2395337B (en) | 2002-11-14 | 2005-12-28 | Gary Michael Wilson | Warning Unit |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US7067298B2 (en) | 2003-03-31 | 2006-06-27 | Ambion, Inc. | Compositions and methods of using a synthetic Dnase I |
| US7666417B2 (en) | 2003-04-22 | 2010-02-23 | Fred Hutchinson Cancer Research Center | Methods and compositions for treating autoimmune diseases or conditions |
| US7754209B2 (en) * | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| US9296820B2 (en) | 2003-11-05 | 2016-03-29 | Roche Glycart Ag | Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| RU2370276C2 (ru) | 2003-12-31 | 2009-10-20 | Мерк Патент Гмбх | Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ |
| SI1706424T1 (sl) | 2004-01-12 | 2010-01-29 | Applied Molecular Evolution | Variante fc regij |
| US7544487B2 (en) | 2004-02-13 | 2009-06-09 | Immunomedics, Inc. | Fusion proteins containing recombinant cytotoxic RNAses |
| EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| JP2008505853A (ja) | 2004-04-13 | 2008-02-28 | クインテセンス バイオサイエンシーズ インコーポレーティッド | 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体 |
| WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
| AU2005334481A1 (en) | 2004-08-11 | 2007-01-25 | Trubion Pharmaceuticals, Inc. | Binding domain fusion proteins |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| DE102005000921A1 (de) | 2005-01-07 | 2006-07-27 | Siemens Ag | Verfahren und Vorrichtung zur Broadband-Datenverteilung zwischen mehreren Benutzerendgeräten |
| DE102005009219A1 (de) | 2005-02-25 | 2006-08-31 | Martin-Luther-Universität Halle-Wittenberg | Ribonuclease-Tandemenzyme und Verfahren zu ihrer Herstellung |
| US20110123440A1 (en) | 2005-03-29 | 2011-05-26 | Genevieve Hansen | Altered Antibody FC Regions and Uses Thereof |
| BRPI0611445A2 (pt) | 2005-05-09 | 2010-09-08 | Glycart Biotechnology Ag | molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica |
| EP1896579A2 (en) | 2005-06-16 | 2008-03-12 | Wisconsin Alumni Research Foundation | Cytotoxic ribonuclease variants |
| EP1910541B1 (en) | 2005-06-16 | 2010-10-20 | Wisconsin Alumni Research Foundation | Cytotoxic ribonuclease variants |
| US20080279850A1 (en) | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
| RU2423381C2 (ru) | 2005-07-25 | 2011-07-10 | Трабьон Фармасьютикалз, Инк. | Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул |
| US7807409B2 (en) | 2005-10-21 | 2010-10-05 | Roche Palo Alto Llc | Method for the recombinant expression of a polypeptide |
| AU2007238034A1 (en) | 2006-04-14 | 2007-10-25 | Trubion Pharmaceuticals Inc. | Binding proteins comprising immunoglobulin hinge and Fc regions having altered Fc effector functions |
| US20100015661A1 (en) * | 2006-04-21 | 2010-01-21 | Mab-Factory Gmbh | Antibody-rnase-conjugate |
| GB0611444D0 (en) | 2006-06-09 | 2006-07-19 | Medical Res Council Technology | Rnase H2 complex and genes therefor |
| NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| EP1905841A1 (en) | 2006-09-25 | 2008-04-02 | Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; | Trex1 as a marker for lupus erythematosus |
| EP2144930A1 (en) * | 2007-04-18 | 2010-01-20 | ZymoGenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| US20090258005A1 (en) | 2007-05-29 | 2009-10-15 | Trubion Pharmaceuticals Inc. | Therapeutic compositions and methods |
| JP2010531137A (ja) | 2007-06-12 | 2010-09-24 | ワイス・エルエルシー | 抗ｃｄ２０治療用組成物および方法 |
| JP2010532764A (ja) * | 2007-07-06 | 2010-10-14 | トゥルビオン・ファーマシューティカルズ・インコーポレーテッド | Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド |
| WO2009015345A1 (en) | 2007-07-25 | 2009-01-29 | Amgen Inc. | Pharmaceutical compositions comprising fc fusion proteins |
| BRPI0814465B1 (pt) | 2007-07-26 | 2021-11-23 | Novagen Holding Corporation | Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica |
| CA2705542A1 (en) | 2007-11-13 | 2009-05-22 | Sapphire Energy, Inc. | Production of fc-fusion polypeptides in eukaryotic algae |
| RU2531754C2 (ru) | 2008-04-11 | 2014-10-27 | ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US | Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством |
| CN102224258A (zh) * | 2008-09-26 | 2011-10-19 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗、诊断和监测狼疮的方法 |
| BRPI0920743A2 (pt) | 2008-10-01 | 2016-09-20 | Quintessence Biosciences Inc | ribonucleases terapeuticas |
| MX341084B (es) | 2009-11-02 | 2016-08-05 | Univ Washington | Composiciones de nucleasas terapéuticas y métodos. |
| TWI529163B (zh) | 2011-01-25 | 2016-04-11 | 陶氏農業科學公司 | 用於製備４－胺基－５－氟－３－鹵素－６－（經取代之）吡啶甲酸酯的方法 |
| EA201370187A1 (ru) | 2011-02-23 | 2013-12-30 | Амген Инк. | Клеточная культуральная среда для уфс воздействия и относящиеся к ней способы |
| MX363013B (es) | 2011-02-25 | 2019-03-04 | Recombinetics Inc | Animales genéticamente modificados y métodos para su obtención. |
| RS61447B1 (sr) | 2011-04-21 | 2021-03-31 | Glaxo Group Ltd | Modulacija ekspresije virusa hepatitisa b (hbv) |
| ES2666303T3 (es) | 2011-04-29 | 2018-05-03 | University Of Washington | Composiciones terapéuticas de nucleasa y métodos |
| US20140178479A1 (en) | 2011-08-12 | 2014-06-26 | Perosphere, Inc. | Concentrated Felbamate Formulations for Parenteral Administration |
| WO2013180295A1 (ja) | 2012-06-01 | 2013-12-05 | 日本電信電話株式会社 | パケット転送処理方法およびパケット転送処理装置 |
| HRP20192080T1 (hr) | 2013-10-31 | 2020-02-07 | Resolve Therapeutics, Llc | Terapeutske fuzije nukleaza-albumine i postupci |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
| CA3029627A1 (en) | 2016-07-01 | 2018-01-04 | Resolve Therapeutics, Llc | Optimized binuclease fusions and methods |
| JP6866739B2 (ja) * | 2017-04-13 | 2021-04-28 | 住友ゴム工業株式会社 | ゴムクローラ |
-
2012
- 2012-04-27 ES ES12777116.0T patent/ES2666303T3/es active Active
- 2012-04-27 KR KR1020257006611A patent/KR20250037576A/ko active Pending
- 2012-04-27 PL PL12777116T patent/PL2704737T3/pl unknown
- 2012-04-27 PH PH1/2013/502441A patent/PH12013502441B1/en unknown
- 2012-04-27 PE PE2013002425A patent/PE20141172A1/es not_active Application Discontinuation
- 2012-04-27 EP EP18167227.0A patent/EP3449933A1/en active Pending
- 2012-04-27 IL IL300276A patent/IL300276B2/en unknown
- 2012-04-27 EA EA201391585A patent/EA201391585A1/ru unknown
- 2012-04-27 SG SG10201913930UA patent/SG10201913930UA/en unknown
- 2012-04-27 KR KR1020207027463A patent/KR102428875B1/ko active Active
- 2012-04-27 NZ NZ616989A patent/NZ616989A/en unknown
- 2012-04-27 KR KR1020197021908A patent/KR102161657B1/ko active Active
- 2012-04-27 CN CN201711217220.XA patent/CN107964539B/zh active Active
- 2012-04-27 WO PCT/US2012/035614 patent/WO2012149440A2/en not_active Ceased
- 2012-04-27 AU AU2012249360A patent/AU2012249360B2/en active Active
- 2012-04-27 KR KR1020237037142A patent/KR102776415B1/ko active Active
- 2012-04-27 HR HRP20180564TT patent/HRP20180564T1/hr unknown
- 2012-04-27 DK DK12777116.0T patent/DK2704737T3/en active
- 2012-04-27 MX MX2013012612A patent/MX351953B/es active IP Right Grant
- 2012-04-27 MX MX2017014091A patent/MX389061B/es unknown
- 2012-04-27 HU HUE12777116A patent/HUE038759T2/hu unknown
- 2012-04-27 US US13/822,215 patent/US10202588B2/en active Active
- 2012-04-27 KR KR1020227026432A patent/KR102596953B1/ko active Active
- 2012-04-27 SI SI201231276T patent/SI2704737T1/en unknown
- 2012-04-27 CN CN201280032451.2A patent/CN103930127B/zh active Active
- 2012-04-27 EP EP12777116.0A patent/EP2704737B1/en active Active
- 2012-04-27 SG SG2013080148A patent/SG194680A1/en unknown
- 2012-04-27 CA CA2834626A patent/CA2834626A1/en active Pending
- 2012-04-27 IL IL313299A patent/IL313299A/en unknown
- 2012-04-27 LT LTEP12777116.0T patent/LT2704737T/lt unknown
- 2012-04-27 JP JP2014508143A patent/JP6063450B2/ja active Active
- 2012-04-27 KR KR1020137031347A patent/KR102006393B1/ko active Active
- 2012-04-27 BR BR112013027547-2A patent/BR112013027547B1/pt active IP Right Grant
-
2013
- 2013-10-24 IL IL229074A patent/IL229074B/en active IP Right Grant
- 2013-10-25 DO DO2013000250A patent/DOP2013000250A/es unknown
- 2013-10-28 CL CL2013003123A patent/CL2013003123A1/es unknown
- 2013-10-29 MX MX2021015735A patent/MX2021015735A/es unknown
- 2013-11-15 CR CR20130598A patent/CR20130598A/es unknown
- 2013-11-27 CO CO13279038A patent/CO6811815A2/es unknown
- 2013-11-28 EC ECSP13013060 patent/ECSP13013060A/es unknown
-
2014
- 2014-02-06 US US14/174,167 patent/US8937157B2/en active Active
-
2015
- 2015-01-19 US US14/599,567 patent/US10000745B2/en active Active
-
2016
- 2016-03-22 AU AU2016201790A patent/AU2016201790B2/en active Active
- 2016-12-16 JP JP2016243950A patent/JP2017114854A/ja active Pending
-
2018
- 2018-02-14 AU AU2018201073A patent/AU2018201073C1/en active Active
- 2018-09-21 JP JP2018177009A patent/JP6762345B2/ja active Active
- 2018-12-21 US US16/229,431 patent/US11034944B2/en active Active
-
2019
- 2019-08-29 IL IL269020A patent/IL269020B/en unknown
-
2020
- 2020-03-04 AU AU2020201619A patent/AU2020201619C1/en active Active
- 2020-09-08 JP JP2020150220A patent/JP7212016B2/ja active Active
-
2021
- 2021-05-19 US US17/324,641 patent/US12338466B2/en active Active
- 2021-08-31 IL IL285985A patent/IL285985B2/en unknown
-
2022
- 2022-06-03 AU AU2022203877A patent/AU2022203877B2/en active Active
-
2023
- 2023-01-12 JP JP2023003096A patent/JP7551794B2/ja active Active
-
2024
- 2024-05-10 JP JP2024077060A patent/JP2024099851A/ja active Pending
- 2024-09-03 JP JP2024151150A patent/JP2024167368A/ja active Pending
-
2025
- 2025-05-23 US US19/217,745 patent/US20260043012A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014519809A5 (https=) | ||
| JP2013509201A5 (https=) | ||
| JP2024167368A5 (https=) | ||
| JP2020203926A5 (https=) | ||
| US12152060B2 (en) | Interleukin-2 variants and methods of uses thereof | |
| US20230355728A1 (en) | Peptidic chimeric antigen receptor t cell switches and uses thereof | |
| HRP20170757T1 (hr) | Terapeutski pripravci nukleaze i postupci | |
| JP2021007390A5 (https=) | ||
| JP6199298B2 (ja) | メグルミンによって安定化されたエタネルセプト製剤 | |
| JP6463968B2 (ja) | アルギニンを含まない腫瘍壊死因子受容体：ｆｃ融合ポリペプチド組成物およびその使用方法 | |
| CN103930127B (zh) | 治疗性核酸酶组合物和方法 | |
| JP2019530430A5 (https=) | ||
| EP3201231B1 (en) | Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28 | |
| JP2009500457A5 (https=) | ||
| AU2016287209A1 (en) | Glucagon derivative and a composition comprising a long acting conjugate of the same | |
| JP2018516566A5 (https=) | ||
| JP2022002513A (ja) | Ｕｔｉ融合タンパク質 | |
| JP2019503706A5 (https=) | ||
| JP2019501925A5 (https=) | ||
| CA2610804C (en) | Process for the purification of il-18 binding protein | |
| JP2009513689A5 (https=) | ||
| JP2024515607A (ja) | 抗炎症性シグレックタンパク質ならびにその製造方法及び使用方法 | |
| JP2023538533A (ja) | 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１ | |
| JP2023526551A (ja) | グルカゴン誘導体の持続型結合体の液状製剤 | |
| HRP20201752T1 (hr) | Terapeutski pripravci nukleaze i postupci |